Blood Res.  2014 Jun;49(2):80-82. 10.5045/br.2014.49.2.80.

Current status and future directions of clinical research and practice in adult acute lymphoblastic leukemia patients in Korea

• Kim DY
• Moon JH
• Joo YD

• KMID: 2172800
• DOI: http://doi.org/10.5045/br.2014.49.2.80

Abstract

No abstract available.

MeSH Terms

Adult*
Humans
Korea
Precursor Cell Lymphoblastic Leukemia-Lymphoma*

Reference

1. Lee SM, Lee WS, Shin HJ, et al. Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia. Ann Hematol. 2013; 92:1101–1110. PMID: 23558905.

2. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002; 20:2464–2471. PMID: 12011123.

3. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009; 27:911–918. PMID: 19124805.

4. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002; 99:863–871. PMID: 11806988.

5. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009; 113:4153–4162. PMID: 19141862.

6. Kim DY, Joo YD, Kim SD, et al. Nilotinib combined with multi-agent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: final results of prospective multicenter phase 2 study. Blood. 2013; 122:abst 55. ASH Annual Meeting.

7. Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011; 118:6521–6528. PMID: 21931113.

8. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111:1827–1833. PMID: 18048644.

9. Lee KH, Lee JH, Lee JH, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011; 118:2609–2617. PMID: 21715313.